Shreepal Pharma Organic Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 04-07-2024
- Paid Up Capital ₹ 6.03 M
as on 04-07-2024
- Company Age 32 years 11 months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 27.50 M
as on 04-07-2024
- Satisfied Charges ₹ 971.95 M
as on 04-07-2024
- Revenue 2145060.00%
FY 2020
- Profit 2458.95%
FY 2020
- Ebitda 48.48%
FY 2020
- Net Worth 6.33%
FY 2020
- Total Assets -40.22%
FY 2020
About Shreepal Pharma Organic
The Company is engaged in the Chemicals And Resources Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 6.03 M.
The Corporate currently has active open charges totaling ₹2.75 Cr. It has already closed loans amounting to ₹97.20 Cr, as per the Ministry of Corporate Affairs (MCA) records.
Chetankumar Shah and Hemali Shah serve as directors at the Company.
- CIN/LLPIN
U24231GJ1991PTC016482
- Company No.
016482
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Oct 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Bhavnagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shreepal Pharma Organic?
Board Members(2)
Financial Performance and Corporate Structure Insights of Shreepal Pharma Organic.
Shreepal Pharma Organic Pvt Ltd, for the financial year ended 2020, experienced significant growth in revenue, with a 2145060% increase. The company also saw a substantial improvement in profitability, with a 2458.95% increase in profit. The company's net worth moved up by a moderate rise of 6.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shreepal Pharma Organic?
In 2020, Shreepal Pharma Organic had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Yash Gases Private Limited
Active
13 years 6 months Chetankumar Shah and Hemali Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 13 Oct 2011 | ₹2.75 Cr | Open |
State Bank Of India Creation Date: 17 Sep 2013 | ₹1.40 Cr | Satisfied |
Punjab National Bank Creation Date: 09 Jun 2011 | ₹8.50 M | Satisfied |
How Many Employees Work at Shreepal Pharma Organic?
Unlock and access historical data on people associated with Shreepal Pharma Organic, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shreepal Pharma Organic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shreepal Pharma Organic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
